30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Immunome Inc (IMNM)

Track

Over the last 90 days, Immunome Inc. has seen significant insider selling activity, with a net value of -$730,644.5. Notably, an executive reported a proposed sale of $1,117,800. While there were some insider buys totaling $1,012,621.5, the overall trend indicates net selling pressure.
Stock chart
Ticker: IMNM Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Rosett Max
Chief Financial Officer
2 sales — total 200,000 USD
Planned sale 15 Jun 2026
Value US$2,869,621.30 | Price 286.48 | Shares 45,405
Proposed sale 15 Jun 2026
Value US$3,473,061.60 | Price 252.99 | Shares 14,982
Buy 5 Jun 2026
Value US$2,641,660.72 | Price 89.48 | Shares 49,465
Buy 5 Jun 2026
Value US$4,625,965.40 | Price 422.88 | Shares 81,448
Buy 5 Jun 2026
Value US$100,000.00 | Price 19.46 | Shares 1,000
Buy 5 Jun 2026
Value US$100,000.00 | Price 19.46 | Shares 1,000
Buy 5 Jun 2026
Value US$100,000.00 | Price 19.48 | Shares 1,000
Buy 5 Jun 2026
Value US$100,000.00 | Price 19.48 | Shares 1,000
Sale 5 Jun 2026
Value US$100,000.00 | Price 19.41 | Shares 1,000
Sale 5 Jun 2026
Value US$100,000.00 | Price 19.41 | Shares 1,000
Sale 5 Jun 2026
Value US$100,000.00 | Price 19.44 | Shares 1,000
Sale 5 Jun 2026
Value US$100,000.00 | Price 19.44 | Shares 1,000
Buy 15 May 2026
Value US$103,500.00 | Price 20.70 | Shares 5,000
Planned sale 2 Apr 2026
Value US$204,238.32 | Price 21.64 | Shares 9,438
Proposed sale 2 Apr 2026
Value US$204,238.32 | Price 21.64 | Shares 9,438
Planned sale 2 Apr 2026
Value US$30,213.12 | Price 22.48 | Shares 1,344
Planned sale 2 Apr 2026
Value US$1,394,702.96 | Price 21.91 | Shares 63,656
Proposed sale 2 Apr 2026
Value US$1,425,084.64 | Price 21.92 | Shares 65,000
Proposed sale 2 Apr 2026
Value US$4,723,550.00 | Price 72.67 | Shares 65,000
Buy 27 Mar 2026
Value US$500,601.50 | Price 19.67 | Shares 25,450
Sale 23 Mar 2026
Value US$582,330.00 | Price 20.65 | Shares 28,200
Sale 20 Mar 2026
Value US$753,296.00 | Price 20.47 | Shares 36,800
Proposed sale 20 Mar 2026
Value US$1,352,640.00 | Price 20.81 | Shares 65,000
Buy 11 Mar 2026
Value US$21,550.00 | Price 21.55 | Shares 1,000
Buy 10 Mar 2026
Value US$22,120.00 | Price 22.12 | Shares 1,000
Buy 30 Dec 2025
Value US$100,018.35 | Price 21.15 | Shares 4,729
Planned sale 22 Dec 2025
Value US$251,347.34 | Price 22.34 | Shares 11,251
Planned sale 22 Dec 2025
Value US$8,078,732.28 | Price 21.72 | Shares 371,949
Buy 19 Dec 2025
Value US$149,053.44 | Price 20.48 | Shares 7,278
Buy 19 Dec 2025
Value US$204,900.00 | Price 20.49 | Shares 10,000
Buy 18 Dec 2025
Value US$999,986.50 | Price 21.50 | Shares 46,511
Buy 3 Jun 2025
Value US$46,900.00 | Price 9.38 | Shares 5,000
Buy 26 Mar 2025
Value US$999,459.00 | Price 7.29 | Shares 137,100
Buy 25 Mar 2025
Value US$60,684.00 | Price 7.78 | Shares 7,800
Buy 24 Mar 2025
Value US$57,470.00 | Price 8.21 | Shares 7,000
Buy 24 Mar 2025
Value US$103,566.00 | Price 8.42 | Shares 12,300
Buy 31 Jan 2025
Value US$1,162,500.00 | Price 7.75 | Shares 150,000
Buy 22 Nov 2024
Value US$331,918.41 | Price 9.78 | Shares 33,943
Buy 21 Nov 2024
Value US$630,263.05 | Price 9.54 | Shares 66,057
Buy 21 Nov 2024
Value US$149,799.79 | Price 9.48 | Shares 15,805
Buy 21 Nov 2024
Value US$198,030.00 | Price 9.43 | Shares 21,000
Sale 19 Sep 2024
Value US$230,223.80 | Price 16.01 | Shares 14,380
Proposed sale 19 Sep 2024
Value US$230,210.98 | Price 16.01 | Shares 14,380
Buy 16 Aug 2024
Value US$97,608.00 | Price 13.94 | Shares 7,000
Sale 15 Aug 2024
Value US$49,071.70 | Price 13.93 | Shares 3,524
Proposed sale 15 Aug 2024
Value US$49,073.22 | Price 13.93 | Shares 3,524
Buy 21 May 2024
Value US$27,139.80 | Price 13.57 | Shares 2,000
Buy 21 May 2024
Value US$281,547.83 | Price 13.78 | Shares 20,434
Buy 20 May 2024
Value US$1,106,524.36 | Price 13.91 | Shares 79,566
Buy 2 Oct 2023
Value US$999,995.64 | Price 5.91 | Shares 169,204
Buy 2 Oct 2023
Value US$249,993.00 | Price 5.91 | Shares 42,300
Buy 13 Sep 2021
Value US$518,201.52 | Price 19.96 | Shares 25,962
Buy 10 Sep 2021
Value US$276,675.00 | Price 17.85 | Shares 15,500
Buy 9 Sep 2021
Value US$411,288.80 | Price 18.46 | Shares 22,280
Buy 9 Sep 2021
Value US$142,484.80 | Price 17.44 | Shares 8,170
Buy 26 May 2021
Value US$25,405.05 | Price 19.03 | Shares 1,335
Buy 26 May 2021
Value US$43,562.00 | Price 18.94 | Shares 2,300
Buy 25 May 2021
Value US$50,064.60 | Price 18.44 | Shares 2,715
Buy 25 May 2021
Value US$193,305.00 | Price 18.41 | Shares 10,500
Buy 25 May 2021
Value US$353,630.96 | Price 18.32 | Shares 19,303
Buy 24 May 2021
Value US$10,680.00 | Price 17.80 | Shares 600
Buy 24 May 2021
Value US$586,230.10 | Price 18.38 | Shares 31,895
Buy 24 May 2021
Value US$94,795.16 | Price 18.58 | Shares 5,102
Buy 24 May 2021
Value US$6,232.72 | Price 18.44 | Shares 338
Buy 6 Oct 2020
Value US$999,984.00 | Price 12.00 | Shares 83,332
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-17 2026-06-15 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
45,405 -18.0%
286.48
US$2,869,621 		45,405 -18.0% 286.48 US$2,869,621
2026-06-15 2026-06-15 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
14,982
252.99
US$3,473,062 		14,982 252.99 US$3,473,062
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
49,465 +8.7%
89.48
US$2,641,661 		49,465 +8.7% 89.48 US$2,641,661
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.4%
19.27
US$100,000 		1,000 +2.4% 19.27 US$100,000
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +9.0%
19.46
US$100,000 		1,000 +9.0% 19.46 US$100,000
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +9.0%
19.46
US$100,000 		1,000 +9.0% 19.46 US$100,000
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +18.2%
19.48
US$100,000 		1,000 +18.2% 19.48 US$100,000
2026-06-09 2026-06-05 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +18.2%
19.48
US$100,000 		1,000 +18.2% 19.48 US$100,000
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -23.3%
19.41
US$100,000 		1,000 -23.3% 19.41 US$100,000
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -23.3%
19.41
US$100,000 		1,000 -23.3% 19.41 US$100,000
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -1.2%
19.44
US$100,000 		1,000 -1.2% 19.44 US$100,000
2026-06-09 2026-06-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -1.2%
19.44
US$100,000 		1,000 -1.2% 19.44 US$100,000
2026-05-19 2026-05-15 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +13.0%
20.70
US$103,500 		5,000 +13.0% 20.70 US$103,500
2026-04-03 2026-04-02 PlS Planned sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
9,438 -30.0%
21.64
US$204,238 		9,438 -30.0% 21.64 US$204,238
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
1,344 -2.4%
22.48
US$30,213 		1,344 -2.4% 22.48 US$30,213
2026-04-03 2026-04-02 PlS Planned sale
3.3
Rosett Max

Chief Financial Officer

Officer
63,656 -53.5%
21.91
US$1,394,703 		63,656 -53.5% 21.91 US$1,394,703
2026-04-03 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
21.92
US$1,425,085 		65,000 21.92 US$1,425,085
2026-04-02 2026-04-02 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
65,000
72.67
US$4,723,550 		65,000 72.67 US$4,723,550
2026-04-02 2026-04-02 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
9,438
21.64
US$204,238 		9,438 21.64 US$204,238
2026-03-31 2026-03-27 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
25,450 +3.8%
19.67
US$500,602 		25,450 +3.8% 19.67 US$500,602
2026-03-23 2026-03-23 S Sale
WAGENHEIM PHILIP
Non-Executive Director
28,200 -7.6%
20.65
US$582,330 		28,200 -7.6% 20.65 US$582,330
2026-03-23 2026-03-20 S Sale
WAGENHEIM PHILIP
Non-Executive Director
36,800 -9.1%
20.47
US$753,296 		36,800 -9.1% 20.47 US$753,296
2026-03-20 2026-03-20 PrS Proposed sale
WAGENHEIM PHILIP

Director

Non-Executive Director
65,000
20.81
US$1,352,640 		65,000 20.81 US$1,352,640
2026-03-12 2026-03-11 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
21.55
US$21,550 		1,000 +2.7% 21.55 US$21,550
2026-03-12 2026-03-10 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +2.7%
22.12
US$22,120 		1,000 +2.7% 22.12 US$22,120
2025-12-30 2025-12-30 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
4,729 +0.7%
21.15
US$100,018 		4,729 +0.7% 21.15 US$100,018
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
11,251 -0.6%
22.34
US$251,347 		11,251 -0.6% 22.34 US$251,347
2025-12-23 2025-12-22 PlS Planned sale
Barchas Isaac
Non-Executive Director
371,949 -15.4%
21.72
US$8,078,732 		371,949 -15.4% 21.72 US$8,078,732
2025-12-22 2025-12-19 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
7,278 +0.9%
20.48
US$149,053 		7,278 +0.9% 20.48 US$149,053
2025-12-22 2025-12-19 B Purchase
3.5
Tsai Philip

Chief Technical Officer

Officer
10,000 +30.0%
20.49
US$204,900 		10,000 +30.0% 20.49 US$204,900
2025-12-18 2025-12-18 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
46,511 +5.8%
21.50
US$999,986 		46,511 +5.8% 21.50 US$999,986
2025-06-03 2025-06-03 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
5,000 +15.9%
9.38
US$46,900 		5,000 +15.9% 9.38 US$46,900
2025-03-26 2025-03-26 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
137,100 +20.5%
7.29
US$999,459 		137,100 +20.5% 7.29 US$999,459
2025-03-26 2025-03-25 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,800 +33.0%
7.78
US$60,684 		7,800 +33.0% 7.78 US$60,684
2025-03-25 2025-03-24 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +42.1%
8.21
US$57,470 		7,000 +42.1% 8.21 US$57,470
2025-03-25 2025-03-24 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
12,300 +58.6%
8.42
US$103,566 		12,300 +58.6% 8.42 US$103,566
2025-02-03 2025-01-31 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
150,000 +28.9%
7.75
US$1,162,500 		150,000 +28.9% 7.75 US$1,162,500
2024-11-25 2024-11-22 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
33,943 +7.0%
9.78
US$331,918 		33,943 +7.0% 9.78 US$331,918
2024-11-25 2024-11-21 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
66,057 +15.7%
9.54
US$630,263 		66,057 +15.7% 9.54 US$630,263
2024-11-25 2024-11-21 B Purchase
2.2
Lechleider Robert

Chief Medical Officer

Officer
15,805 +inf%
9.48
US$149,800 		15,805 +inf% 9.48 US$149,800
2024-11-25 2024-11-21 B Purchase
3.5
Tsai Philip

Chief Technology Officer

Officer
21,000 +inf%
9.43
US$198,030 		21,000 +inf% 9.43 US$198,030
2024-09-20 2024-09-19 S Sale
3.3
Rosett Max

Chief Financial Officer

Officer
14,380 -23.2%
16.01
US$230,224 		14,380 -23.2% 16.01 US$230,224
2024-09-19 2024-09-19 PrS Proposed sale
3.3
Rosett Max

Officer

Officer
14,380
16.01
US$230,211 		14,380 16.01 US$230,211
2024-08-19 2024-08-16 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
7,000 +72.8%
13.94
US$97,608 		7,000 +72.8% 13.94 US$97,608
2024-08-19 2024-08-15 S Sale
2.2
Higgins Jack

Chief Scientific Officer

Officer
3,524 -18.0%
13.93
US$49,072 		3,524 -18.0% 13.93 US$49,072
2024-08-15 2024-08-15 PrS Proposed sale
2.2
Higgins Jack

Officer

Officer
3,524
13.93
US$49,073 		3,524 13.93 US$49,073
2024-05-22 2024-05-21 B Purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
2,000 +26.3%
13.57
US$27,140 		2,000 +26.3% 13.57 US$27,140
2024-05-21 2024-05-21 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
20,434 +5.1%
13.78
US$281,548 		20,434 +5.1% 13.78 US$281,548
2024-05-21 2024-05-20 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
79,566 +24.9%
13.91
US$1,106,524 		79,566 +24.9% 13.91 US$1,106,524
2023-10-04 2023-10-02 B Purchase
3.3
SIEGALL CLAY B

President and CEO

Executive Director
169,204 +112.5%
5.91
US$999,996 		169,204 +112.5% 5.91 US$999,996
2023-10-04 2023-10-02 B Purchase
Turner Bruce

Chief Strategy Officer

Officer
42,300 +inf%
5.91
US$249,993 		42,300 +inf% 5.91 US$249,993
2021-09-14 2021-09-13 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
25,962 +14.2%
19.96
US$518,202 		25,962 +14.2% 19.96 US$518,202
2021-09-13 2021-09-10 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
15,500 +9.3%
17.85
US$276,675 		15,500 +9.3% 17.85 US$276,675
2021-09-13 2021-09-09 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
22,280 +15.4%
18.46
US$411,289 		22,280 +15.4% 18.46 US$411,289
2021-09-13 2021-09-09 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
8,170 +6.0%
17.44
US$142,485 		8,170 +6.0% 17.44 US$142,485
2021-05-26 2021-05-26 B Purchase
1.8
Lefenfeld Michael
Non-Executive Director
1,335 +5.2%
19.03
US$25,405 		1,335 +5.2% 19.03 US$25,405
2021-05-26 2021-05-26 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
2,300 +1.7%
18.94
US$43,562 		2,300 +1.7% 18.94 US$43,562
2021-05-26 2021-05-25 B Purchase
1.8
Lefenfeld Michael
Non-Executive Director
2,715 +11.9%
18.44
US$50,065 		2,715 +11.9% 18.44 US$50,065
2021-05-26 2021-05-25 B Purchase
1.5
Sarma Purnanand D

President and CEO

Executive Director
10,500 +inf%
18.41
US$193,305 		10,500 +inf% 18.41 US$193,305
2021-05-26 2021-05-25 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
19,303 +16.8%
18.32
US$353,631 		19,303 +16.8% 18.32 US$353,631
2021-05-26 2021-05-24 B Purchase
1.8
Lefenfeld Michael
Non-Executive Director
600 +2.7%
17.80
US$10,680 		600 +2.7% 17.80 US$10,680
2021-05-26 2021-05-24 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
31,895 +38.3%
18.38
US$586,230 		31,895 +38.3% 18.38 US$586,230
2021-05-26 2021-05-24 B Purchase
3.7
LAMATTINA JOHN L
Non-Executive Director
5,102 +10.9%
18.58
US$94,795 		5,102 +10.9% 18.58 US$94,795
2021-05-26 2021-05-24 B Purchase
3.7
LAMATTINA JOHN L
Non-Executive Director
338 +0.7%
18.44
US$6,233 		338 +0.7% 18.44 US$6,233
2020-10-08 2020-10-06 B Purchase
2.4
RAPP MICHAEL
Non-Executive Director
83,332 +15.0%
12.00
US$999,984 		83,332 +15.0% 12.00 US$999,984
Explore more

More insider trading research around Immunome Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America